NCT03601819 is a Phase 1 clinical trial of Pacritinib in Lymphoma, T-Cell, Cutaneous, sponsored by University of Michigan Rogel Cancer Center.

Who is sponsoring NCT03601819?

NCT03601819 is sponsored by University of Michigan Rogel Cancer Center.

What drugs are being tested in NCT03601819?

Interventions in NCT03601819: Pacritinib.

What condition does NCT03601819 study?

NCT03601819 studies Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Chronic Lymphocytic Leukemia, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma.

Is NCT03601819 still recruiting?

NCT03601819 is currently terminated. Last updated 22 January 2021.

Last reviewed 2021-01-22 · How we verify

NCT03601819

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Terminated Phase 1 Last updated 22 January 2021

What this trial tests

Phase 1 trial testing Pacritinib in Lymphoma, T-Cell, Cutaneous in 4 participants. Terminated before completion.

Timeline

15 May 2019

Primary endpoint
7 March 2020

17 July 2020

Quick facts

Lead sponsor	University of Michigan Rogel Cancer Center
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	15 May 2019
Primary completion	7 March 2020
Estimated completion	17 July 2020
Sites	1 location across United States

Drugs / interventions tested

Pacritinib (PACRITINIB) — full drug profile →

Conditions studied

Lymphoma, T-Cell, Cutaneous — all drugs for Lymphoma, T-Cell, Cutaneous →
Lymphoma, T-Cell, Peripheral — all drugs for Lymphoma, T-Cell, Peripheral →
Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
Lymphoproliferative Disorders — all drugs for Lymphoproliferative Disorders →

Sponsor

University of Michigan Rogel Cancer Center

Who can join

18 and older, any sex, with Lymphoma, T-Cell, Cutaneous or Lymphoma, T-Cell, Peripheral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation and tumor progression: signaling pathways and targeted intervention.
Zhao H, Wu L, Yan G, Chen Y, et al · · 2021 · cited 1932× · PMID 34248142 · DOI 10.1038/s41392-021-00658-5
The force awakens: metastatic dormant cancer cells.
Park SY, Park SY, Nam JS. · · 2020 · cited 149× · PMID 32300189 · DOI 10.1038/s12276-020-0423-z
Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.
Lees C, Keane C, Gandhi MK, Gunawardana J. · · 2019 · cited 44× · PMID 30740662 · DOI 10.1111/bjh.15778
JAK/STAT in leukemia: a clinical update.
Liang D, Wang Q, Zhang W, Tang H, et al · · 2024 · cited 38× · PMID 38273387 · DOI 10.1186/s12943-023-01929-1
Insights into the role of the JAK/STAT signaling pathway in graft-<i>versus</i>-host disease.
Abboud R, Choi J, Ruminski P, Schroeder MA, et al · · 2020 · cited 33× · PMID 32537114 · DOI 10.1177/2040620720914489
Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y, Che J, Wu M, Guo Y, et al · · 2022 · cited 26× · PMID 35303910 · DOI 10.1186/s13045-022-01249-9
Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
De Togni E, Cole O, Abboud R. · · 2024 · cited 7× · PMID 38380328 · DOI 10.3389/fimmu.2024.1304065
Janus kinase inhibitors - a role for the treatment of cutaneous T-cell lymphomas?
Packer SE, Brunner PM. · · 2025 · PMID 40861896 · DOI 10.3389/or.2025.1482866

Verify or expand the search:

Other trials of Pacritinib

Trials testing the same drug.

NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym · Phase 1 · recruiting
NCT07447817 — Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias · Phase 2 · not yet recruiting
NCT07148947 — Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant · Phase 2 · recruiting
NCT07226713 — Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatmen · Phase 2 · not yet recruiting
NCT06986174 — A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi · Phase 2 · recruiting

Other recruiting trials for Lymphoma, T-Cell, Cutaneous

Currently open trials in the same condition.

NCT03902184 — IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma · Phase 2 · active not recruiting

Other University of Michigan Rogel Cancer Center trials

Trials by the same sponsor.

NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
NCT07481344 — SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners · NA · not yet recruiting
NCT07526545 — Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial · NA · not yet recruiting
NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
NCT07365007 — A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Ca · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03601819 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan Rogel Cancer Center
Last refreshed: 22 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03601819.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing